Health-Tech Startup Oncare Raises ₹27 Crore in Series A
What happened
Oncare, a health-technology startup, has raised ₹27 crore in a Series A funding round led by Sky Impact Capital. The investment reflects continued venture capital interest in technology-enabled models focused on service distribution and accessibility.
Why it matters
- Oncare operates on a "hospital-in-hospital" model, establishing and managing specialized oncology departments within existing mid-sized, non-branded hospitals. This capital-efficient approach avoids the high cost of building new facilities and is designed for rapid scaling. - The startup was founded in 2023 by Amar Sneh and Deepak Kumar, both of whom previously worked at the surgical care platform Pristyn Care. - A key part of Oncare's strategy is to make cancer treatment more affordable, claiming its chemotherapy prices are about 40% lower and surgeries are 30-40% cheaper than at large corporate hospitals. - The fresh capital is earmarked for expansion beyond its four current centers in Delhi-NCR, with plans to launch in Bangalore and several Tier 2 and Tier 3 cities, particularly in Uttar Pradesh, Bihar, and West Bengal, where there is a significant gap in accessible cancer care. - Since its inception, the company has interacted with approximately 30,000 patients, leading to 3,000 oncologist consultations and treatment for about 1,000 patients. - This Series A round included participation from other investors such as Huddle Ventures, Lotus Herbal Group, Steerx, and Tremis Capital. - Prior to this round, Oncare raised a $1 million seed round in October 2024, which was led by Huddle Ventures. - The company aims to address the lack of accessible, quality cancer care in India, a market projected to reach ₹43,000 crore by FY28.
Key numbers
- Oncare, a health-technology startup, has raised ₹27 crore in a Series A funding round led by Sky Impact Capital.
- The startup was founded in 2023 by Amar Sneh and Deepak Kumar, both of whom previously worked at the surgical care platform Pristyn Care.
- A key part of Oncare's strategy is to make cancer treatment more affordable, claiming its chemotherapy prices are about 40% lower and surgeries are 30-40% cheaper than at large corporate hospitals.
- Since its inception, the company has interacted with approximately 30,000 patients, leading to 3,000 oncologist consultations and treatment for about 1,000 patients.
What happens next
- The company aims to address the lack of accessible, quality cancer care in India, a market projected to reach ₹43,000 crore by FY28.
Quick answers
What happened in Health-Tech Startup Oncare Raises ₹27 Crore in Series A?
Oncare, a health-technology startup, has raised ₹27 crore in a Series A funding round led by Sky Impact Capital. The investment reflects continued venture capital interest in technology-enabled models focused on service distribution and accessibility.
Why does Health-Tech Startup Oncare Raises ₹27 Crore in Series A matter?
Oncare operates on a "hospital-in-hospital" model, establishing and managing specialized oncology departments within existing mid-sized, non-branded hospitals. This capital-efficient approach avoids the high cost of building new facilities and is designed for rapid scaling. The startup was founded in 2023 by Amar Sneh and Deepak Kumar, both of whom previously worked at the surgical care platform Pristyn Care. A key part of Oncare's strategy is to make cancer treatment more affordable, claiming its chemotherapy prices are about 40% lower and surgeries are 30-40% cheaper than at large corporate hospitals. The fresh capital is earmarked for expansion beyond its four current centers in Delhi-NCR, with plans to launch in Bangalore and several Tier 2 and Tier 3 cities, particularly in Uttar Pradesh, Bihar, and West Bengal, where there is a significant gap in accessible cancer care. Since its inception, the company has interacted with approximately 30,000 patients, leading to 3,000 oncologist consultations and treatment for about 1,000 patients. This Series A round included participation from other investors such as Huddle Ventures, Lotus Herbal Group, Steerx, and Tremis Capital. Prior to this round, Oncare raised a $1 million seed round in October 2024, which was led by Huddle Ventures. The company aims to address the lack of accessible, quality cancer care in India, a market projected to reach ₹43,000 crore by FY28.
